Log on / register
Feedback | Support | My details
Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis.
Bagshaw SM, Ghali WA
BMC Med 2004 Oct 22, 2:38
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Research    
N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial
Amini M, Salarifar M, Amirbaigloo A, Masoudkabir F, Esfahani F
Trials 2009, 10:45 (29 June 2009)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
2.


Study protocol    
Rationale, design, and baseline characteristics of the Acetylcystein for Contrast-Induced nephropaThy (ACT) Trial: a pragmatic randomized controlled trial to evaluate the efficacy of acetylcysteine for the prevention of contrast-induced nephropathy
The ACT Trial Investigators
Trials 2009, 10:38 (4 June 2009)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
3.


Editorial    
BMC Medicine celebrates its 5th anniversary
Appleford JM, Cassady-Cain RL, Patel J, Norton ML
BMC Medicine 2009, 7:3 (15 January 2009)
 [Abstract] [Full text] [PDF]
4.


Research article    
A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity
Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, Natanson C, Danner RL
BMC Medicine 2007, 5:32 (14 November 2007)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

This article is also cited by a further 2 articles in PubMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.